3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead

Key Points

• Inventiva, Larimar Therapeutics, and Ascentage Pharma Group International are small-cap biotech stocks that analysts have given consensus Buy ratings with triple-digit upside price targets.
• Each company faces a key catalyst, including Inventiva's Phase 3 MASH trial results, Larimar's FDA submission for nomlabofusp, and Ascentage's international regulatory expansion.
• All three stocks have fallen significantly from one-year highs, and two remain pre-revenue with mounting losses, while Ascentage alone generates growing commercial revenue.

Small-cap stocks tend to fly under the radar. Often in startup stages, these companies can lack analyst coverage, be overlooked by institutional investors, and be illiquid due to low average trading volume.

But occasionally, some small caps present investment theses that are so compelling that they begin to command attention.

But three biotech companies—Inventiva NASDAQ: IVA, Larimar Therapeutics NASDAQ: LRMR, and Ascentage Pharma Group International NASDAQ: AAPG—have catalysts that could put them on more investors' radars.

Each is developing treatments for serious diseases with significant unmet medical needs, and all three carry consensus analyst price targets suggesting triple-digit upside. While clinical, regulatory, and financial risks remain substantial, upcoming drug-development milestones could help determine whether Wall Street's optimism is justified.

Inventiva's Phase 3 MASH Results Could Be a Major Stock Catalyst

Headquartered in France, Inventiva is a clinical-stage pharmaceutical company that develops an investigational oral therapy for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease associated with metabolic disorders.

Inventiva’s most promising product, lanifibranor, is an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist that simultaneously activates all three PPAR subtypes.

The drug is currently being evaluated in the company's Phase 3 NATiV3 trial, with topline results expected in Q4 2026. Positive results could support a potential U.S. regulatory submission in the first half of 2027, making the upcoming readout a significant catalyst for investors.

While MASH affects approximately 5% of adults globally, an estimated 9 million to 15 million U.S. adults suffer from the disease. And its prevalence is forecast to rise substantially due to increasing rates of obesity, insulin resistance, type 2 diabetes, and metabolic syndrome.

As a clinical-stage biopharma with no approved commercial products, Inventiva is pre-revenue. While lanifibranor works its way through the pipeline, the company has seen its net losses mount, increasing annually from $34 million in 2019 to $416 million in 2025.

Shares are down more than 58% from their one-year high, but the stock carries an analyst consensus Buy rating and its $15.86 price target indicates over 400% upside potential.

Larimar Moves Closer to FDA Approval for Its Lead Drug

Larimar Therapeutics is a clinical-stage biotech company focused on developing treatments for rare diseases caused by deficiencies in mitochondrial proteins.

Its lead drug candidate, nomlabofusp, is an engineered fusion protein designed to deliver frataxin to mitochondria, which is being developed primarily for the treatment of Friedreich’s ataxia, a rare, inherited neurodegenerative disorder.

Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, aiming to address an underlying cause of the disease rather than only treating its symptoms.

As its therapeutics are also in the development stage, Larimar is also pre-revenue. Because of that, the company’s net losses have been increasing, from $35 million in 2022 to $166 million in 2025.

But on June 29, Larimar announced it submitted the first module of its rolling Biologics License Application submission to the U.S. Food and Drug Administration for accelerated approval of nomlabofusp. The remaining modules are expected to be submitted before the end of 2026.

Shares are down 58% from their one-year high and short interest of 13.93% of the float remains a concern. But analysts have given LRM a consensus Buy rating and assigned it a $10.33 price target which implies more than 280% potential upside.

Ascentage's China Success Sets the Stage for U.S. Expansion

Of the three stocks on this list, shares of Ascentage Pharma Group International have fared the worst over the past year, having fallen nearly 64% from their one-year high.

The commercial-stage pharmaceutical company is focusing on developing therapies that target mechanisms involved in programmed cell death, or apoptosis, primarily directed toward cancer and other serious diseases. Its pipeline includes small-molecule drug candidates designed to inhibit proteins that help cancer cells survive.

Two of its leading candidates are lisaftoclax and APG-115. Lisaftoclax is a BCL-2 inhibitor already approved in China for certain previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma patients, with additional clinical trials underway in other hematologic malignancies. APG-115, an MDM2-p53 inhibitor under evaluation for oncology applications.

Ascentage has also developed candidates targeting inhibitor-of-apoptosis proteins and other applications that are relevant to cancer treatment.

The company conducts research and clinical-development activities in China and has pursued international development and regulatory opportunities, including in the United States. While some of its drugs are already approved in China, others remain subject to clinical testing and regulatory review, and approved uses may vary by geography.

It is important to note that, unlike the other two companies, Ascentage generates commercial revenue.

In its Aug. 19 H1 2026 earnings release (which covers the first six months of 2026), the company reported revenue of $44.5 million, up 29% year over year, primarily driven by sales of its oncology drugs, including olverembatinib and lisaftoclax.

The stock carries a consensus Buy rating from analysts, who have given AAPG a $44,75 price target, suggesting more than 200% potential upside.